These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25100513)

  • 1. Letter campaign sought to pressure FDA action on stem cell clinics.
    Dolgin E
    Nat Med; 2014 Aug; 20(8):796-7. PubMed ID: 25100513
    [No Abstract]   [Full Text] [Related]  

  • 2. Stem cells. U.S. regulation of stem cells as medical products.
    Sipp D; Turner L
    Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA should stand firm on stem-cell treatments.
    Nature; 2016 Jul; 535(7610):7-8. PubMed ID: 27383946
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA challenges stem-cell clinic.
    Cyranoski D
    Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
    [No Abstract]   [Full Text] [Related]  

  • 5. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 6. Texas prepares to fight for stem cells.
    Cyranoski D
    Nature; 2011 Sep; 477(7365):377-8. PubMed ID: 22049545
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA device approval regulations.
    Savage RA
    Hum Pathol; 1994 May; 25(5):548-9. PubMed ID: 8200653
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA statutory authority to regulate the safety of dietary supplements.
    Hutt PB
    Am J Law Med; 2005; 31(2-3):155-74. PubMed ID: 16146287
    [No Abstract]   [Full Text] [Related]  

  • 9. The Growing "Stem Cell Clinic" Problem.
    Kuriyan AE; Albini TA; Flynn HW
    Am J Ophthalmol; 2017 May; 177():xix-xx. PubMed ID: 28366429
    [No Abstract]   [Full Text] [Related]  

  • 10. Stem cell clinics: risk of proliferation.
    Sissung TM; Figg WD
    Lancet Oncol; 2020 Feb; 21(2):205-206. PubMed ID: 32007195
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 12. The US Food and Drug Administration Modernization Act of 1997: impact on consumers.
    Golodner LF
    Clin Ther; 1998; 20 Suppl C():C20-5. PubMed ID: 9915086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injured consumers and the FDA. Should federal preemption protect medical device manufacturers under a quasi-governmental immunity?
    Truitt BI
    J Leg Med; 1994 Mar; 15(1):155-84. PubMed ID: 8201276
    [No Abstract]   [Full Text] [Related]  

  • 14. Understanding FDA regulation of DTC genetic tests within the context of administrative law.
    Wagner JK
    Am J Hum Genet; 2010 Oct; 87(4):451-6. PubMed ID: 20920664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
    Nguyen D; Seoane-Vazquez E; Rodriguez-Monguio R; Montagne M
    BMC Health Serv Res; 2013 Jan; 13():27. PubMed ID: 23339419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FDA defense: a prescription for easing the pain of punitive damage awards in medical products liability cases.
    Marthaler AL
    Spec Law Dig Health Care Law; 1997 Sep; (223):9-45. PubMed ID: 10173273
    [No Abstract]   [Full Text] [Related]  

  • 17. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

  • 18. Deadly dimethylamylamine: "health" supplements are killing consumers while current regulations impede FDA action.
    Palmer PG
    J Leg Med; 2014; 35(2):311-36. PubMed ID: 24896317
    [No Abstract]   [Full Text] [Related]  

  • 19. The need for FDA regulation of tobacco products.
    Kennedy EM
    Yale J Health Policy Law Ethics; 2002; 3(1):101-8. PubMed ID: 12825428
    [No Abstract]   [Full Text] [Related]  

  • 20. Dirty dancing--the FDA stumbles with the Chevron two-step: a response to professor Noah.
    Lawson G
    Cornell Law Rev; 2008 Jul; 93(5):927-38. PubMed ID: 18618964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.